Identification of a novel GNAS mutation in a family with pseudohypoparathyroidism type 1A

Fabio Sippelli,Silvana Briuglia,Chiara Ferraloro,Anna Paola Capra,Emanuele Agolini,Tiziana Abbate,Giorgia Pepe,Tommaso Aversa,Malgorzata Wasniewska,Domenico Corica

DOI: https://doi.org/10.1186/s12887-024-04761-8

2024-04-27

BMC Pediatrics

Abstract:Pseudohypoparathyroidism (PHP) is caused by loss-of-function mutations at the GNAS gene (as in the PHP type 1A; PHP1A), de novo or inherited at heterozygous state, or by epigenetic alterations at the GNAS locus (as in the PHP1B). The condition of PHP refers to a heterogeneous group of disorders that share common clinical and biological features of PTH resistance. Manifestations related to resistance to other hormones are also reported in many patients with PHP, in association with the phenotypic picture of Albright hereditary osteodystrophy characterized by short stature, round facies, subcutaneous ossifications, brachydactyly, mental retardation and, in some subtypes, obesity. The purpose of our study is to report a new mutation in the GNAS gene and to describe the significant phenotypic variability of three sisters with PHP1A bearing the same mutation.

pediatrics

What problem does this paper attempt to address?

The problem this paper attempts to address is the description of a novel GNAS gene mutation and the exploration of why three sisters with pseudohypoparathyroidism type 1A (PHP1A), despite carrying the same gene mutation, exhibit significantly different clinical phenotypes and biochemical characteristics. Through this case study, the authors aim to reveal the extent of genotype-phenotype variability in PHP1A and emphasize the importance of early diagnosis and long-term multidisciplinary follow-up in patient care.

Specifically, the paper reports a novel GNAS gene mutation (NM_000516.5 c.118_139 + 51del), which leads to the observed extensive clinical heterogeneity and biochemical differences among the three sisters. These findings are significant for understanding the genetic basis of PHP1A, increasing awareness of the disease, and improving clinical management and treatment strategies for patients.